Wedbush Forecasts Increased Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received revised earnings predictions from Wedbush, a research firm that anticipates the company will perform better than previously expected. In a report released on December 23, 2024, Wedbush analyst L. Chico updated the earnings per share (EPS) forecast for the first quarter of 2025, now estimating it to be $1.52, up from an earlier estimate of $1.49.

Analyst Recommendations

Wedbush's analysis includes maintaining an "Outperform" rating on Neurocrine Biosciences, with a price target set at $148.00 per share. The consensus estimate for the company's full-year earnings is $3.94 per share. Additionally, Wedbush estimates future quarterly earnings for Q2 2025 at $1.82 EPS, Q3 2025 at $1.90 EPS, Q4 2025 at $2.46 EPS, and annual earnings for FY2025 and FY2026 projected at $7.71 EPS and $10.87 EPS, respectively.

Market Perspective

Other analysts have also commented on Neurocrine Biosciences' stock. William Blair reiterated an "outperform" rating on December 16, while BMO Capital Markets adjusted their price target downward from $128.00 to $114.00, maintaining a "market perform" rating on October 17. Piper Sandler and Cantor Fitzgerald both reiterated an "overweight" rating, with price targets of $160.00 and $155.00, respectively. Needham & Company LLC expressed a "hold" rating in a separate report. Overall, market data indicates that Neurocrine Biosciences holds a consensus rating of "Moderate Buy" among analysts, with an average target price of $166.29.

Current Stock Performance

Neurocrine Biosciences shares opened at $136.99 recently and have shown a 50-day moving average of $124.40 and a 200-day moving average of $130.59. The company's market capitalization stands at approximately $13.87 billion, with a price-to-earnings (P/E) ratio of 36.73 and a beta of 0.34. Over the past year, the stock has fluctuated between a low of $110.95 and a high of $157.98.

Institutional Activity

Recent trading activity has seen several hedge funds engage with Neurocrine Biosciences shares. Ashton Thomas Private Wealth LLC and Innealta Capital LLC each bought new positions during the second quarter, valued at around $28,000 and $30,000 respectively. Additionally, Blue Trust Inc. increased its stake by 171.9% during the third quarter, now holding 348 shares worth about $40,000. Other funds, like Plato Investment Management Ltd and Truvestments Capital LLC, have also expanded their portfolios with shares of this company, with institutional ownership totaling approximately 92.59% of the stock.

Insider Trading Activity

Recent insider transactions include the sale of shares by Ingrid Delaet and Jude Onyia. Delaet sold 1,091 shares on December 17 at an average price of $135.00, totaling $147,285.00, which reduced her holdings by 30.32%. Onyia sold 2,331 shares on November 29, with a total transaction value of nearly $294,382, marking a 13.11% decrease in his ownership. These transactions reflect ongoing internal adjustments within the company, with corporate insiders collectively holding about 4.30% of the stock.

Company Overview

Neurocrine Biosciences, Inc. is focused on the discovery, development, and marketing of pharmaceutical products aimed at treating neurological, neuroendocrine, and neuropsychiatric disorders. Notable products include INGREZZA, which treats tardive dyskinesia, and other medications such as ALKINDI, Efmody, Orilissa, and Oriahnn, which serve different medical needs.

Earnings, Stocks, Neurocrine